Match Document Document Title
9028808 Methods for treating nicotine addiction and reducing food consumption  
The present invention relates to a cytokine for use in the treatment and/or control of dependent and/or addictive behavior, in particular addiction and/or dependency to nicotine, food addiction,...
9023337 Method for treating deficiency in hematopoiesis  
Methods for enhancing or stimulating hematopoiesis including the step of administering Interleukin-12 (IL-12) to yield hematopoietic recovery in a mammal in need. Preferred methods include the...
9017654 Preparation for vaccination, vaccination method and use of a vaccination preparation  
The present invention relates to a pharmaceutical preparation, comprising at least one Toll-like receptor ligand and at least one peptide. The invention also relates to the use of such a...
9011833 Vitamin E formulations of sulfamide NS3 inhibitors  
The invention relates to new formulations of compounds having activity against HCV-associated disorders, new combinations, new methods of treatment and their use in therapy.
9005600 Compounds useful for multi-level specific targeting of cancer cells  
A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13Rα2 binding ligand; at least one effector molecule (e.g., one, two, three or more...
9005599 Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents  
The invention provides methods of preventing or treating diseases or disorders caused by biological agents or chemical agents in a subject (e.g., a mammal, such as a human) by administering...
8992904 ***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***
Anti-IL-6 antibodies or fragments thereof to treat or inhibit cachexia, associated with chemotherapy toxicity
 
The present invention is directed to therapeutic methods and compositions, especially subcutaneous and intravenous composition using antibodies and fragments thereof having binding specificity for...
8980244 Method of treating type 1 diabetes by administering NKp46 polypeptide  
The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention...
8974776 Biodegradable peptide releasing polymers  
Novel biodegradable compositions are disclosed. The biodegradable compositions include at least one hydroxyl-terminated component and at least one bioactive peptide in a linear chain. The...
8968716 In situ-forming hydrogel for tissue adhesives and biomedical use thereof  
Disclosed herein are an in situ-forming, bioadhesive hydrogel and the medical uses thereof. Being formed by in situ crosslinking through an enzymatic reaction, the hydrogel has an advantage over...
8961950 Neoadjuvant treatment of cancer with proleukin  
Low doses of IL-2 are administered locally and neo-adjuvantly to patients with early stages of the disease. This will result in local high concentrations of IL-2 within the relevant tumor draining...
8956605 Prevention and/or treatment of multiple organ dysfunction syndrome with interleukin-22  
The present invention relates to use an agent for the prevention and/or treatment of multiple organ dysfunction syndrome (MODS) or multiple organ failure (MOF) comprising interleukin-22 (IL-22) as...
8945528 Use of interleukin-22 in treating viral hepatitis  
This invention relates to a use of IL-22 in the treatment of viral hepatitis. As illustrated in the examples of this invention, IL-22 can significantly reduce liver damage caused by hepatitis...
8945623 Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use  
The invention provides compositions, kits, and methods for treatment of neuronal injury. In one embodiment, the composition comprises a biomembrane sealing agent, such as PEG, and a bioactive...
8940289 Fusion molecules and IL-15 variants  
The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making such proteins. The instant invention...
8926957 Methods of using IL-31 antagonists in diseases mediated by cutaneous lymphocyte antigen positive T cells  
The present invention relates to predicting therapeutic response of treating patients suffering from itching and pruritis mediated by cutaneous lymphocyte antigen positive T cells in atopic...
8920790 Uses of IL-12 in hematopoiesis  
Methods for enhancing or stimulating hematopoiesis including the step of administering Interleukin-12 (IL-12) to yield hematopoietic recovery in a mammal in need. Preferred methods include the...
8921315 Method of increasing survival of a human subject having exposure to an acute exposure to non-therapeutic whole body ionization by administering a therapeutically effective dose of IL-12  
The present invention provides methods for increasing survival in a subject, and/or preserving bone marrow function, and/or promoting hematopoietic recovery or restoration. The methods include...
8920808 Cytokine-based fusion proteins for treatment of multiple sclerosis  
The present invention provides fusion proteins including an autoimmune antigen, an allergen antigen or an alloantigen, and an anti-inflammatory cytokine. Compositions and methods including the...
8916616 Multi-functional polymeric materials and their uses  
Multifunctional polymers are disclosed having a smart segment and a biodegradable segment. Advantageously, the biodegradable segment includes a hydrophilic segment and a hydrophobic segment....
8906846 Method of treating inflammatory bowel disease by administering a clip-inducing agent  
The disclosure relates to methods for treating disorders of the mucosal tract such as the gastrointestinal system by targeting CLIP molecules. The methods are based on that CLIP in the groove of...
8906356 Mutant interleukin-2 (IL-2) polypeptides  
The present invention relates to mutant IL-2 polypeptides that act as receptor antagonists. The mutant IL-2 polypeptides bind CD 25 but do not activate the IL-2 receptor. Also provided are methods...
8906858 Method for the prophylactic or therapeutic treatment of glucocorticoid-induced osteoporosis  
The present invention relates to a method for the prophylactic and/or therapeutic treatment of glucocorticoid induced osteoporosis comprising maintaining or restoring AP-1 activity or...
8900565 Indole derivatives as inhibitors of histone deacetylase  
Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using...
8900566 Hepatitis C virus inhibitors  
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such...
8895501 Eye-drop vaccine containing copolymer 1 for therapeutic immunization  
The invention provides an eye-drop vaccine for therapeutic immunization of a mammal comprising Copolymer 1, a Copolymer 1-related peptide, or a Copolymer 1-related polypeptide, for treating...
8894989 PARP inhibitor compounds, compositions and methods of use  
The present invention relates to tetraaza phenalen-3-one compounds which inhibit poly(ADP-ribose) polymerase (PARP) and are useful in the chemosensitization of cancer therapeutics. The induction...
8895709 Isolation and purification of antibodies using protein A affinity chromatography  
Disclosed herein are methods for the isolation and purification of antibodies wherein the use of an affinity chromatographic step results in an antibody composition sufficiently pure for...
8894990 Method for treating psoriatic arthritis by administering an anti-IL-12 antibody  
An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47,...
8883134 Human interleukin-1 receptor antagonist—hybrid Fc fusion protein  
The present disclosure provides a fusion protein comprising IL-1 receptor antagonist fused to a hybrid Fc. Particularly the present disclosure relates to a fusion protein comprising IL-1 receptor...
8871192 IL-1F8 polypeptides  
The present invention provides compositions and methods relating to IL-1Rrp2 requiring proteins.
8871191 Use of IL-15 preparations to treat lymphopenia  
The present invention provides method for promoting the maturation and export of T cells from thymic tissue by contacting the thymic tissue with supraphysiological levels of interleukin (IL)-15....
8865652 Method of treating solid cancers with pegylated IL-10  
Provided are methods of treatment for tumors. In particular, methods are provided for use of a chemically modified IL-10 to treat tumors.
8846024 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)  
An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo- 4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3 -car...
8846023 Hepatitis C virus inhibitors  
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such...
8846098 Artificial cell constructs for cellular manipulation  
The present invention contemplates induction of immunological tolerance thereby providing permanent allograft acceptance. This method obviates the need for a lifelong regimen of immunosuppressive...
8840878 Peptidomimetic sulfamide compounds and antiviral uses thereof  
The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
8840915 Pharmaceutical compositions for sustained release delivery of peptides  
The present invention provides methods of forming a solid, biodegradable implant in-situ in a body by administering a liquid pharmaceutical composition comprising an effective amount of a...
8835613 β-mannosylceramide and stimulation of NKT cell anti-tumor immunity  
β-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of...
8828375 Expansion of haemopoietic precursors  
The present invention relates to a method of transplanting haematopoietic precursor cells into a subject in need thereof which involves culturing the haematopoietic precursor cells in the presence...
8821851 Inflammation-inhibitory serum factors and uses thereof  
Disclosed are methods of purifying compounds that reduce or prevent an inflammatory response in a mammal, use of such compounds in treating a mammal having or being at risk of developing...
8816053 Methods for treating viral infection using IL-28 and IL-29 cysteine mutants  
IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on...
8815229 Granulysin in immunotherapy  
Methods of stimulating or enhancing an immune response in a host are disclosed. The methods include contacting a monocyte with 15 kD granulysin thereby producing a monocyte-derived dendritic cell....
8809562 Use of metallocene compounds for cancer treatment  
Metallocene compounds and pharmaceutical compositions containing these metallocene compounds are disclosed and described. Methods of treating cancer employing such metallocene compounds and...
8802076 Compositions and methods for modulating an immune response  
Provided are nanoparticles comprising heparin, chitosan, and at least one immunomodulatory agent, e.g. a cytokine. The cytokine can be selected from the group consisting of TNF, IL-12, IL-2,...
8784796 Vaccine immunotherapy for treating hepatocellular cancer in immune suppressed patients  
A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naive T-cells and restoring T-cell immunity. A method of vaccine immunotherapy includes the...
8771701 Compositions for immunotherapy and uses thereof  
The present invention relates to a method of eliciting a cytotoxic T lymphocyte response to an antigen in an animal, the method comprising pulsing mannose receptor-bearing antigen presenting cells...
8771664 Compositions comprising apolipoprotein A polypeptide and interleukin 15, and methods of treatment using the same  
The present invention relates to compositions capable of promoting both the innate immune response as well as the adaptive immune response in a subject based on the jointly use of ApoA,...
8765115 Method of treatment of gastrointestinal disorders with IL-10  
Providing a new method of treating inflammatory gastrointestinal disorders and a food product for the prevention or improvement of inflammatory gastrointestinal disorders. Prevention or treatment...
8765914 Interleukin-B30 proteins  
Purified genes encoding a cytokine referred to as interleukin-B30 (IL-B30) from a mammal, and reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding...